Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
GenMark Diagnostics, Inc (NASDAQ:GNMK) surged 12 percent Wednesday after announcing FDA market clearance for its ePlex Blood Culture Identification Fungal Pathogen Panel. The news bolstered Raymond James' bullish thesis for the stock.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Raymond James analyst John Hsu maintained a Market Outperform rating on GenMark with a $7 price target.
The Thesis
The second of three ePlex panels was set to cover more fungal pathogens than any competing product. GenMark boosted the candidate’s appeal by achieving clearance sooner than Raymond James had expected, Hsu said in a Wednesday note.
“Importantly, with today's FDA clearance, we see the regulatory hurdles as further derisked and supportive of our positive thesis in a 31-percent revenue CAGR through 2020, driven by continued ePlex platform utilization and menu expansion,” the analyst said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Looking ahead, Raymond James anticipates a 10-percent year-over-year increase in annuity per placement. Additionally, because the testing is inpatient, the analyst considers it insulated from insurance decisions that affect outpatient reimbursement.
GenMark awaits clearance of its gram negative panel to seize a $500-million total addressable market for sepsis prevention, and altogether, the panel trio will detect pathogens that cause more than 95 percent of bloodstream infections, according to Raymond James.
Until then, the fungus panel on its own is seen to meet a high demand as fungal pathogens increase as a cause of blood infections.
Price Action
GenMark shares were down 2.51 percent at $4.28 at the time of publication Thursday.
Related Links:
6 Valuable Pipeline Drugs With Upcoming Catalysts
Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.